Related Experiment Video
Updated: Dec 30, 2025
11:02
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
983
Metabolomics in multiple sclerosis disease course and progression.
Pavan Bhargava1, Daniel C Anthony2
1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|January 23, 2020
Summary
Metabolomics reveals significant metabolic changes in multiple sclerosis (MS). This approach can differentiate MS patients, predict disease progression, and identify new therapeutic targets for this neurological condition.
Area of Science:
- Neuroscience
- Biochemistry
- Genomics
Background:
- Multiple sclerosis (MS) is a chronic neurological disease characterized by changes in the metabolome.
- Numerous studies have utilized diverse metabolomics platforms across various biological samples, consistently revealing alterations in metabolic pathways in MS patients.
Purpose of the Study:
- To review the diagnostic and prognostic capabilities of metabolomics in multiple sclerosis.
- To explore the potential of metabolomics in disease staging, progression monitoring, and personalized therapy selection.
- To discuss metabolomics' role in uncovering disease pathophysiology and identifying therapeutic targets.
Main Methods:
- Review of existing studies employing metabolomics platforms on various biological materials (e.g., brain tissue, urine).
- Analysis of research focusing on the differentiation of MS patients from healthy controls and other neurological diseases.
- Examination of studies exploring predictive modeling for MS disease staging and progression.
Main Results:
- Metabolomics can effectively differentiate MS patients from healthy controls and other neurological conditions.
- Evidence suggests the potential for metabolomics-based predictive models for disease staging and monitoring.
- Metabolomics offers insights into MS pathophysiology and identifies potential therapeutic targets.
Conclusions:
- Metabolomics shows promise for developing diagnostic and prognostic biomarkers for multiple sclerosis.
- The integration of metabolomics with other omics techniques is crucial for a comprehensive understanding of MS.
- Metabolomics can guide the identification of novel therapeutic strategies for multiple sclerosis.
